Cargando…

Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China

Stage IV breast cancer is metastatic breast cancer (MBC). Because real-world data are lacking in China, our research attempts to explore the effect of locoregional surgery on the prognosis of patients with MBC. A total of 987 patients from 10 hospitals and 2 databases in East China (2004–2018) were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Li, Mi, Yunzhe, Cui, Shude, Wang, Haibo, Fu, Peifen, Yin, Yongmei, Jin, Feng, Li, Jianbin, Liu, Yinhua, Fan, Zhimin, Zhang, Haiqing, Geng, Cuizhi, Jiang, Zefei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582173/ https://www.ncbi.nlm.nih.gov/pubmed/33093581 http://dx.doi.org/10.1038/s41598-020-75119-0

Ejemplares similares

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021
por: Li, Jianbin, et al.
Publicado: (2023)

Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer
por: Zhu, Jiujun, et al.
Publicado: (2021)

Role of Locoregional Treatment in De Novo Stage IV Breast Cancer
por: Lee, Joanna S, et al.
Publicado: (2020)

Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
por: Zeng, Fujuan, et al.
Publicado: (2021)

Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology
por: Merloni, Filippo, et al.
Publicado: (2023)

Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020
por: Li, Jianbin, et al.
Publicado: (2020)

Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer
por: Chen, Peng-Yu, et al.
Publicado: (2013)

Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis
por: Gera, Ritika, et al.
Publicado: (2020)

ASO Author Reflections: Real-World Conclusions on Locoregionally Recurrent Colon Cancer
por: Swartjes, Hidde, et al.
Publicado: (2022)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
por: Zhao, Wei, et al.
Publicado: (2020)

Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma
por: Wang, Yu-Wen, et al.
Publicado: (2020)

The optimization of postoperative radiotherapy in de novo stage IV breast cancer: evidence from real-world data to personalize treatment decisions
por: Miyashita, Minoru, et al.
Publicado: (2023)

Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence
por: Bowes, Kathleen, et al.
Publicado: (2022)

Locoregional therapy in de novo metastatic breast cancer. The unanswered question
por: Cardoso, Maria-Joao, et al.
Publicado: (2021)

Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients
por: Signoriello, Simona, et al.
Publicado: (2012)

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
por: Yuan, Yang, et al.
Publicado: (2021)

KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy
por: Huang, Xuchen, et al.
Publicado: (2023)

Clinical predictors of survival in real world practice in stage IV melanoma
por: Hu, Hsien‐Pang, et al.
Publicado: (2022)

Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2018)

Role of PAX2 in breast cancer verified by bioinformatics analysis and in vitro validation
por: Yang, Shan, et al.
Publicado: (2023)

Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China
por: Zhang, Shaohua, et al.
Publicado: (2023)

Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
por: Hu, Y.-J., et al.
Publicado: (2023)

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
por: Yang, Fan, et al.
Publicado: (2020)

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
por: Reinhorn, Daniel, et al.
Publicado: (2021)

Locoregional Therapy in De novo Metastatic Breast Cancer: A Retrospective Cohort Study
por: Jianna, Sun, et al.
Publicado: (2022)

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification
por: Li, Jianbin, et al.
Publicado: (2022)

Incorporation of biologic factors for the staging of de novo stage IV breast cancer
por: He, Zhen-Yu, et al.
Publicado: (2020)

Risk stratification for nasopharyngeal carcinoma: a real-world study based on locoregional extension patterns and Epstein-Barr virus DNA load
por: Zhang, Lu-Lu, et al.
Publicado: (2020)

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma
por: Sun, Meiling, et al.
Publicado: (2022)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yang, Jiangping, et al.
Publicado: (2020)

Impact of breast surgery in de novo stage IV breast cancer
por: Shien, Tadahiko
Publicado: (2019)

Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy
por: Li, W.-Z., et al.
Publicado: (2021)

Could local surgery improve survival in de novo stage IV breast cancer?
por: Xiong, Zhenchong, et al.
Publicado: (2018)

Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
por: Xu, Cheng, et al.
Publicado: (2018)

Radiation therapy for primary tumor of de novo stage IV breast cancer
por: Yoshimura, Michio
Publicado: (2020)

A comparison between clinical decision support system and clinicians in breast cancer
por: Li, Jianbin, et al.
Publicado: (2023)

Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study
por: Cheng, Ying, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1km0cbaja64oncmc7utc45kpin